Zeria Plans 2009 Test Of Compound For Easing Cancer Pain
This article was originally published in PharmAsia News
Japan's Zeria Pharmaceutical says it expects to begin Phase II trials in Europe next year to test its pancreatic cancer compound, Z-360. The drug was developed to treat stomach ulcers, but Zeria redeveloped it to treat gastrointestinal cancers. Z-360 failed in previous trials to shrink tumors, but researchers noted it helped to ease patient pain. In next year's trials, Zeria plans to test the gastrin CCK2 receptor antagonist in combination with Eli Lilly's Gemzar (gemcitabine). (Click here for more - a subscription may be required
You may also be interested in...
In a 1 June speech before the Alliance For a Stronger FDA, US FDA commissioner Stephen Hahn stressed the agency’s vigilance in guarding against consumer use of flawed COVID-19 products. He also made comments about the need for doctors to communicate more with patients. See what he said about the use of telehealth here.
Request for documents and a briefing is part of efforts to ensure federal programs are ‘protected from price gouging.’
Merck’s Frazier Urges Businesses To Use ‘Every Instrument At Their Disposal’ To Reduce Racial Inequity
‘What we have to guard against is that when the streets quiet down … a lot of people are going to go back to their normal lives,’ Merck CEO Ken Frazier says in an interview with CNBC.